<DOC>
	<DOCNO>NCT02224781</DOCNO>
	<brief_summary>This randomized phase III trial study well initial treatment ipilimumab nivolumab follow dabrafenib trametinib work compare initial treatment dabrafenib trametinib follow ipilimumab nivolumab treat patient stage III-IV melanoma contain mutation know BRAFV600 remove surgery . Ipilimumab nivolumab may block tumor growth target certain cell . Dabrafenib trametinib may block tumor growth target BRAFV600 gene . It yet know whether treat patient ipilimumab nivolumab follow dabrafenib trametinib effective treatment dabrafenib trametinib follow ipilimumab nivolumab .</brief_summary>
	<brief_title>Dabrafenib Trametinib Followed Ipilimumab Nivolumab Ipilimumab Nivolumab Followed Dabrafenib Trametinib Treating Patients With Stage III-IV BRAFV600 Melanoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether initial treatment either combination ipilimumab-nivolumab ( subsequent dabrafenib combination trametinib ) dabrafenib combination trametinib ( subsequent ipilimumab-nivolumab ) significantly improve 2 year overall survival ( OS ) patient unresectable stage III stage IV BRAFV600 mutant melanoma . SECONDARY OBJECTIVES : I . To evaluate impact initial treatment median OS hazard ratio death . II . To determine whether initial treatment choice significantly improve 3 year OS . III . To evaluate anti-tumor activity ( Response Evaluation Criteria Solid Tumors [ RECIST ] -defined response rate , median progression-free survival [ PFS ] ) safety profile ipilimumab-nivolumab dabrafenib-trametinib Cooperative Group trial patient V600 mutant melanoma . IV . To evaluate activity ( RECIST-defined response rate , median PFS ) safety dabrafenib-trametinib patient disease progression ipilimumab-nivolumab comparison activity safety ipilimumab-nivolumab naive patient . V. To evaluate activity ipilimumab-nivolumab ( RECIST-defined response rate , median PFS ) safety patient disease progression dabrafenib-trametinib comparison activity safety dabrafenib-trametinib naive patient . VI . To assess feasibility crossover alternative treatment strategy ( percentage patient able crossover one arm complete least initial course treatment cross-over without intervene symptomatic disease progression treatment limit toxicity ) . TERTIARY OBJECTIVES : I . Association inherit variation immune mediate adverse event response ipilimumab/nivolumab . II . To determine association inherit genetic variation immune-associated adverse event patient metastatic melanoma treat ipilimumab contain regimen complete candidate-based gene pathway analyse gene involve lymphocyte activation , cytokine , cytokine receptor within major histocompatibility complex ( MHC ) region agnostic genome-wide single nucleotide polymorphism ( SNP ) -based approach . III . To investigate association inherited genetics survival patient metastatic melanoma treat ipilimumab contain regimen complete candidate-based gene pathway analyse gene involve lymphocyte activation , cytokine profile , cytokine receptor within MHC region agnostic genome-wide SNP-based approach . IV . To replicate genomic marker identify aims independent sample set patient treat ipilimumab contain regimen preliminarily characterize potential functional role complete replication variation associate immune-related adverse event ( irAEs ) survival bio-informatic assessment genomic marker . V. To determine utility circulate BRAF level determine response resistance either BRAF/MEK direct and/or combination immunotherapy patient BRAF mutant melanoma . VI . To determine change blood BRAF level utilize peripheral blood BRAFV600 mutational testing patient stage IV BRAF mutant melanoma correlate response resistance combination BRAF/MEK direct therapy . VII . To determine change blood BRAF level utilize peripheral blood BRAFV600 mutational testing patient stage IV BRAF mutant melanoma correlate response resistance combination immunotherapy . VIII . To compare kinetics peripheral blood BRAFV600 level response resistance group patient receive BRAF target therapy combination immunotherapy initial therapy . IX . To compare kinetics peripheral blood BRAFV600 level response resistance combination BRAF target therapy combination immunotherapy individual patient ( initial treatment v crossover treatment ) . PATIENT REPORTED OUTCOMES OBJECTIVES : I . To evaluate difference overall health initial treatment arm ( dabrafenib + trametinib vs. ipilimumab + nivolumab immunotherapy ) 2 year , account toxicity overall survival . ( Primary ) II . To assess difference overall function 2 year initial treatment dabrafenib + trametinib vs. ipilimumab + nivolumab . ( Secondary ) III . To document effect treatment crossover treatment administration sequence symptom burden overall function . ( Secondary ) IV . To compare difference function symptom treatment sequence ipilimumab + nivolumab ( arm A vs. D ) , dabrafenib + trametinib , ( arm B vs. C ) baseline , 6 week , 12 week , 6 month initiation treatment . V. To describe frequency severity treatment toxicity baseline , 6 week , 12 week , 6 month initiation treatment . OUTLINE : Patients randomize 1 2 treatment arm ( Arm A Arm B ) . ARM A : IMMUNOTHERAPY INDUCTION ( COURSES 1-2 ) : Patients receive nivolumab intravenously ( IV ) 60 minute ipilimumab IV 90 minute day 1 22 . Treatment repeat every 6 week 2 course absence disease progression unacceptable toxicity . IMMUNOTHERAPY MAINTENANCE ( COURSES 3-14 ) : Patients receive nivolumab IV 60 minute day 1 , 15 , 29 . Treatment repeat every 6 week 12 course absence disease progression unacceptable toxicity . Upon disease progression , patient re-register cross Arm C. ARM C : Patients receive dabrafenib orally ( PO ) twice daily ( BID ) trametinib PO daily day 1-42 . Courses repeat every 6 week absence disease progression unacceptable toxicity . ARM B : Patients receive dabrafenib PO BID trametinib PO daily day 1-42 . Courses repeat every 6 week absence disease progression unacceptable toxicity . Upon disease progression , patient re-register cross Arm D. ARM D : IMMUNOTHERAPY INDUCTION ( COURSES 1-2 ) : Patients receive nivolumab IV 60 minute ipilimumab IV 90 minute day 1 22 . Treatment repeat every 6 week 2 course absence disease progression unacceptable toxicity . IMMUNOTHERAPY MAINTENANCE ( COURSES 3-14 ) : Patients receive nivolumab IV 60 minute day 1 , 15 , 29 . Treatment repeat every 6 week 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>STEP 1 Eastern Cooperative Oncology Group ( ECOG ) performance status : 0 1 Women must pregnant breastfeed All female childbearing potential must blood test urine study within 2 week prior registration rule pregnancy A female childbearing potential woman , regardless sexual orientation whether undergone tubal ligation , meet follow criterion : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) Women childbearing potential sexually active male must agree use least two accepted effective method contraception and/or abstain sexual intercourse duration participation study , 4 week treatment dabrafenib 4 month dabrafenib combination trametinib ; woman childbearing potential must use least two accepted effective method contraception and/or abstain sexual intercourse least 5 month last dose nivolumab and/or ipilimumab sexually active male must use least two accepted effective method contraception and/or abstain sexual intercourse least 7 month last dose nivolumab and/or ipilimumab ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Patients must unresectable stage III stage IV disease Patients must measurable disease ; sit disease must evaluate within 4 week prior randomization Patients must histological cytological confirmation melanoma metastatic unresectable clearly progressive NOTE : Any patient BRAFV600 E K mutant melanoma ( whether cutaneous , acral mucosal primary ) meet eligibility criterion eligible participation trial ; patient uveal melanoma eligible trial Patients must BRAFV600E BRAFV600K mutation , identify Food Drug Administration ( FDA ) approve test Clinical Laboratory Improvement Act ( CLIA ) certify lab ; test CLIAcertified lab use nonFDA approved method , information assay must provide ( FDA approve test BRAF V600 mutation melanoma include : THxID BRAF Detection Kit Cobas 4800 BRAF V600 Mutation Test ) Patients may prior systemic therapy adjuvant setting ; however adjuvant treatment must include CTLA4 PD1 pathway block antibody BRAF/MEK inhibitor ; also , patient may prior systemic treatment advance ( measurable metastatic ) disease Patients must discontinue chemotherapy , immunotherapy investigational agent use adjuvant set &gt; = 4 week prior enter study recover adverse event due agent ; mitomycin nitrosoureas must discontinue least 6 week prior enter study ; patient must discontinue radiation therapy &gt; = 2 week prior enter study recover adverse event associate treatment ; prior surgery must &gt; = 4 week registration patient must fully recover postsurgical complication Patients must receive investigational agent study within four week prior registration Patients ineligible currently active central nervous system ( CNS ) metastases ; patient treat brain metastasis ( either surgical resection stereotactic radiosurgery [ SRS ] ) stable head magnetic resonance imaging ( MRI ) contrast compute tomography ( CT ) scan least 4 week follow treatment within 4 week randomization could eligible ; patient must take steroid = &lt; 14 day prior randomization purpose manage brain metastasis ; patient whole brain irradiation treatment CNS metastases ineligible Patients must current malignancy , basal cell skin cancer , squamous cell skin cancer , situ cervical cancer , ductal lobular carcinoma situ breast ; patient malignancy eligible continuously diseasefree &gt; 3 year prior time registration ; patient history RAS mutationpositive tumor eligible regardless interval current study ; Note : prospective RAS testing require ; however , result previous RAS test know , must use assess eligibility White blood count &gt; = 3,000/uL Absolute neutrophil count ( ANC ) &gt; = 1,500/uL Platelet count &gt; = 100,000/uL Hemoglobin &gt; 9 g/dL Serum creatinine = &lt; 1.5 x upper limit normal ( ULN ) serum creatinine clearance ( CrCl ) &gt; = 40 ml/min Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) = &lt; 3 x ULN ( = &lt; 5 x ULN patient document liver metastasis ) Alkaline phosphatase = &lt; 2 x ULN ( = &lt; 5 x ULN patient know liver involvement = &lt; 7 x ULN patient know bone involvement ) Total bilirubin = &lt; 1.5 x ULN except subject normal direct bilirubin know Gilbert 's syndrome Serum lactate dehydrogenase ( LDH ) &lt; 10 X ULN ( patient LDH &gt; 10 X ULN felt aggressive disease consider BRAF inhibitor therapy protocol ) Patients must serious unstable preexist medical condition ( aside malignancy exception specify ) , include limited , ongoing active infection require parenteral antibiotic day 1 , history bleed diathesis need concurrent anticoagulation ( international normalize ratio [ INR ] = &lt; 1.5 partial thromboplastin time [ PTT ] within 1.1 x ULN ) , psychiatric illness/social situation would limit compliance study requirement , interfere subject 's safety , obtain informed consent ; therapeutic level dose warfarin use close monitor prothrombin time ( PT ) /INR site ; exposure may decrease due enzyme induction treatment , thus warfarin dose may need adjust base upon PT/INR ; consequently , discontinue dabrafenib , warfarin exposure may increase thus close monitoring via PT/INR warfarin dose adjustment must make clinically appropriate ; prophylactic low dose warfarin may give maintain central catheter patency Patients must history evidence cardiovascular risk include follow : QT interval correct heart rate use Bazett 's formula ( QTcB ) &gt; = 480 msec . baseline History acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within past 24 week prior registration History prior registration evidence current &gt; = class II congestive heart failure define New York Heart Association ( NYHA ) functional classification system Left ventricular ejection fraction ( LVEF ) = &lt; low limit normal cardiac echocardiogram ( echo ) multi gate acquisition scan ( MUGA ) Intracardiac defibrillator History abnormal cardiac valve morphology ( &gt; = grade 2 ) document ECHO ( subject grade 1 abnormality [ i.e. , mild regurgitation/stenosis ] enter study ) ; subject moderate valvular thickening enter study History evidence current clinically significant uncontrolled cardiac arrhythmia ; clarification : subject atrial fibrillation control &gt; 30 day prior dose eligible Treatment refractory hypertension define blood pressure systolic &gt; 140 mmHg and/or diastolic &gt; 90 mm Hg control antihypertensive therapy Individuals know human immunodeficiency virus ( HIV ) infect eligible ( note : HIV test require entry study ) Patients evidence active hepatitis B virus ( HBV ) hepatitis C Virus ( HCV ) infection eligible ; patient clear HBV HCV infection allow Patients active autoimmune disease history autoimmune disease might recur , may affect vital organ function require immune suppressive treatment include systemic corticosteroid , exclude ; include limited patient history immune relate neurologic disease , multiple sclerosis , autoimmune ( demyelinate ) neuropathy , GuillainBarre syndrome , myasthenia gravis ; systemic autoimmune disease systemic lupus erythematosus ( SLE ) , connective tissue disease , scleroderma , inflammatory bowel disease ( IBD ) , Crohn 's , ulcerative colitis , hepatitis ; patient history toxic epidermal necrolysis ( TEN ) , StevensJohnson syndrome , phospholipid syndrome exclude ; patient vitiligo , endocrine deficiency include thyroiditis manage replacement hormone include physiologic corticosteroid eligible ; patient rheumatoid arthritis arthropathy , Sj√∂gren 's syndrome psoriasis control topical medication patient positive serology , antinuclear antibody ( ANA ) , evaluate presence target organ involvement potential need systemic treatment ; systemic immune suppression deem necessary eligible The following medication nondrug therapy also prohibit treatment study : Other anticancer therapy Other investigational drug Patients take medication substance strong inhibitor inducer CYP3A CYP2C8 ineligible Patients must history retinal vein occlusion ( RVO ) Patients must evidence interstitial lung disease pneumonitis Patients must malabsorption , swallow difficulty , condition would interfere ingestion absorption dabrafenib trametinib STEP 2 ( CROSSOVER ARM FOR PATIENTS WITH PROGRESSIVE DISEASE ) The patient must meet eligibility criterion ( except detail ) time crossover RECIST define measurable disease require Only prior systemic therapy part step 1 allow ; patient receive allowed systemic therapy adjuvant set prior Step 1 eligible Step 1 exclude proceed Step 2 meet eligibility criterion Malabsorption , swallow difficulty , condition would interfere ingestion absorption dabrafenib trametinib , history retinal vein occlusion acceptable patient cross ipilimumab + nivolumab treatment History autoimmune disease , exclude interstitial lung disease pneumonitis , allow patient cross dabrafenib/trametinib therapy Patients le 4 week surgery SRS CNS metastases There restriction serum LDH crossover Patients history cardiovascular risk develop step 1 therapy discuss study principal investigator ( PI ) time crossover Patients must melanoma metastatic clearly progressive prior therapy Patients must least 2 week within 12 week document progressive disease ( PD ) Step 1 current study ; sit disease must evaluate within 4 week prior registration Patients must recover adverse event ( toxicity resolve grade 1 less ) prior therapy ; patient immune related toxicity ipilimumab + nivolumab may continue onto Step 2 even still steroid control side effect , long toxicity resolve grade 1 less Patients must discontinue radiation therapy &gt; = 2 week prior register Step 2 study recover adverse event associate treatment ; prior surgery must &gt; = 2 week registration Step 2 patient must fully recover postsurgical complication Patients ineligible currently active CNS metastasis ; patient treat brain metastasis ( either surgical resection SRS ) stable head MRI contrast CT scan least 4 week follow treatment within 4 week prior Step 2 registration eligible ; patient cross ipilimumab + nivolumab must take steroid = &lt; 14 day prior registration purpose manage brain metastasis ; exclusion apply patient cross dabrafenib + trametinib ; patient whole brain irradiation treatment CNS metastases ineligible Patients must current malignancy , basal cell skin cancer , squamous cell skin cancer , situ cervical cancer , ductal lobular carcinoma situ breast</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>